CTCBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 14, 2024 at 04:28 am
Share
CTCBIO Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported negative sales was KRW 0.00013 million compared to sales of KRW 0.00032 million a year ago. Net loss was KRW 284.01 million compared to KRW 1,711.32 million a year ago.
Basic loss per share from continuing operations was KRW 12 compared to KRW 72 a year ago. Basic loss per share was KRW 12 compared to KRW 72 a year ago.
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
CTCBIO INC. 
